Advertisement

In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC

  • Tatsuki Ueda
  • Shin KanekoEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2048)

Abstract

T cells engineered to express chimeric antigen receptor (CAR) against the B cell antigen CD19 are achieving remarkable clinical effects on hematological malignancies. Allogeneic transplantation approach is promising for broaden application of CART therapy. iPSCs are one of the ideal cell sources for this approach. CAR-engineered iPSCs are demonstrated to give rise to CAR-engineered T cell and exert their effector function. In this section, we describe the method to generate CAR-engineered iPSCs and differentiate them into T cells.

Key words

Chimeric antigen receptor Induced pluripotent stem cells Immunotherapy T cell differentiation Lentiviral transduction 

References

  1. 1.
    Lee DW et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517–528CrossRefGoogle Scholar
  2. 2.
    Maude SL et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507–1517CrossRefGoogle Scholar
  3. 3.
    Davila ML et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25–224ra25CrossRefGoogle Scholar
  4. 4.
    Themeli M, Rivière I, Sadelain M (2015) New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 16:357–366CrossRefGoogle Scholar
  5. 5.
    Qasim W et al (2017) Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med 9:1–9CrossRefGoogle Scholar
  6. 6.
    Nishimura T et al (2013) Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12:114–126CrossRefGoogle Scholar
  7. 7.
    Vizcardo R et al (2013) Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells. Cell Stem Cell 12:31–36CrossRefGoogle Scholar
  8. 8.
    Kitayama S et al (2016) Cellular adjuvant properties, direct cytotoxicity of re-differentiated Vα24 invariant NKT-like cells from human induced pluripotent stem cells. Stem Cell Reports 6:213–227CrossRefGoogle Scholar
  9. 9.
    Themeli M et al (2013) Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol 31:928–933CrossRefGoogle Scholar
  10. 10.
    Zou J et al (2011) Plenary paper oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease – mediated safe harbor targeting. Blood 117:5561–5572CrossRefGoogle Scholar
  11. 11.
    Hong S et al (2007) Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol Ther 15:1630–1639CrossRefGoogle Scholar
  12. 12.
    Jiang H et al (2010) Hemato-endothelial differentiation from lentiviral-transduced human embryonic stem cells retains durable reporter gene expression under the control of ubiquitin promoter. Cytotechnology 62:31–42CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Research and ApplicationKyoto UniversityKyotoJapan
  2. 2.Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and ApplicationKyoto UniversityKyotoJapan

Personalised recommendations